Latest & greatest articles for type 1 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 1 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 1 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 1 diabetes

1. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. (Abstract)

Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. Higher serum urate levels are associated with an increased risk of diabetic kidney disease. Lowering of the serum urate level with allopurinol may slow the decrease in the glomerular filtration rate (GFR) in persons with type 1 diabetes and early-to-moderate diabetic kidney disease.In a double-blind trial, we randomly assigned participants with type 1 diabetes, a serum urate level of at least 4.5 mg per deciliter (...) of serious adverse events was similar in the two groups.We found no evidence of clinically meaningful benefits of serum urate reduction with allopurinol on kidney outcomes among patients with type 1 diabetes and early-to-moderate diabetic kidney disease. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; PERL ClinicalTrials.gov number, NCT02017171.).Copyright © 2020 Massachusetts Medical Society.

2020 NEJM

2. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. (Abstract)

Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. Continuous glucose monitoring (CGM) provides real-time assessment of glucose levels and may be beneficial in reducing hypoglycemia in older adults with type 1 diabetes.To determine whether CGM is effective in reducing hypoglycemia compared with standard blood glucose monitoring (BGM) in older adults with type 1 diabetes.Randomized clinical trial conducted at 22 (...) ); and cognition and patient-reported outcomes, with adjustment for multiple comparisons to control for false-discovery rate.Of the 203 participants (median age, 68 [interquartile range {IQR}, 65-71] years; median type 1 diabetes duration, 36 [IQR, 25-48] years; 52% female; 53% insulin pump use; mean HbA1c, 7.5% [SD, 0.9%]), 83% used CGM at least 6 days per week during month 6. Median time with glucose levels less than 70 mg/dL was 5.1% (73 minutes per day) at baseline and 2.7% (39 minutes per day) during

2020 JAMA

3. Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial. (Abstract)

Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial. Adolescents and young adults with type 1 diabetes exhibit the worst glycemic control among individuals with type 1 diabetes across the lifespan. Although continuous glucose monitoring (CGM) has been shown to improve glycemic control in adults, its benefit in adolescents and young adults has not been demonstrated.To determine the effect of CGM on glycemic (...) control in adolescents and young adults with type 1 diabetes.Randomized clinical trial conducted between January 2018 and May 2019 at 14 endocrinology practices in the US including 153 individuals aged 14 to 24 years with type 1 diabetes and screening hemoglobin A1c (HbA1c) of 7.5% to 10.9%.Participants were randomized 1:1 to undergo CGM (CGM group; n = 74) or usual care using a blood glucose meter for glucose monitoring (blood glucose monitoring [BGM] group; n = 79).The primary outcome was change

2020 JAMA

4. Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association

disease; DPP4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide-1; HDL-C, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; LV, left ventricular; MACE, major adverse cardiovascular event; MI, myocardial infarction; PCSK9, proprotein convertase subtilisin/kexin type 9; SGLT2, sodium-glucose cotransporter 2; and T2DM, type 2 diabetes mellitus. Aspirin and Clopidogrel In the setting of this platelet-centric thrombogenic milieu, medical management with antiplatelet therapies has been (...) . However, because of the higher underlying risk of patients with T2DM, statins often result in greater absolute risk reduction. Among the 20 536 adults in the HPS (Heart Protection Study), which tested once-daily 40 mg simvastatin (versus placebo) in a mix of primary and secondary prevention patients, 5963 participants had diabetes mellitus (615 with type 1 diabetes mellitus), and 3982 had both diabetes mellitus and CAD. The diabetes mellitus subanalysis showed that simvastatin was associated with a 22

2020 American Heart Association

5. The effects of a supportive-educational intervention on women with type 2 diabetes and diabetic peripheral neuropathy: a randomized controlled trial

Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Clin Rehabil Actions . 2020 Jun;34(6):794-802. doi: 10.1177/0269215520914067. Epub 2020 Apr 20. The Effects of a Supportive-Educational Intervention on Women With Type 2 Diabetes and Diabetic Peripheral Neuropathy: A Randomized Controlled Trial , , , Affiliations Expand Affiliations 1 Bohlool Hospital, Gonabad University of Medical Sciences (...) -Educational Intervention on Women With Type 2 Diabetes and Diabetic Peripheral Neuropathy: A Randomized Controlled Trial Zohre Ahrary et al. Clin Rehabil . 2020 Jun . Show details Clin Rehabil Actions . 2020 Jun;34(6):794-802. doi: 10.1177/0269215520914067. Epub 2020 Apr 20. Authors , , , Affiliations 1 Bohlool Hospital, Gonabad University of Medical Sciences, Gonabad, Iran. 2 Department of Community Health Nursing & Management Nursing, School of Nursing, Social Determinants of Health Research Center

2020 EvidenceUpdates

6. A pragmatic study of mid-mixture insulin and basal insulin treatment in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic medications: A lesson from real-world experience Full Text available with Trip Pro

. Ilag LL, et al. Clin Ther. 2007 Jun;29(6 Pt 1):1254-70. doi: 10.1016/j.clinthera.2007.07.003. Clin Ther. 2007. PMID: 18036388 Review. Show more similar articles References REFERENCES World Health Organization. Diabetes. https://www.who.int/news-room/fact-sheets/detail/diabetes. Accessed July 16, 2019. Kaiser AB, Zhang N, Pluijm WVD. Global prevalence of type 2 diabetes over the next ten years (2018-2028); 2018 Poster, Diabetes; 67. Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern (...) A pragmatic study of mid-mixture insulin and basal insulin treatment in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic medications: A lesson from real-world experience A Pragmatic Study of Mid-Mixture Insulin and Basal Insulin Treatment in Patients With Type 2 Diabetes Uncontrolled With Oral Antihyperglycaemic Medications: A Lesson From Real-World Experience - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set

2020 EvidenceUpdates

7. Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB) Full Text available with Trip Pro

to Metformin Plus a Dipeptidyl peptidase-4 Inhibitor in Japanese Patients With Type 2 Diabetes: A Randomized, 24-week, Open-Label, Controlled Trial (STOP-OB) , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan. 2 Seino Internal Medicine Clinic, Koriyama, Japan. 3 Internal Medicine, Oyama East Clinic, Oyama, Japan. 4 Department (...) Inhibitor in Japanese Patients With Type 2 Diabetes: A Randomized, 24-week, Open-Label, Controlled Trial (STOP-OB) Toru Kitazawa et al. Diabetes Obes Metab . 2020 . Show details Diabetes Obes Metab Actions . 2020 Apr 20. doi: 10.1111/dom.14059. Online ahead of print. Authors , , , , , , , , , , Affiliations 1 Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan. 2 Seino Internal Medicine

2020 EvidenceUpdates

8. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial Full Text available with Trip Pro

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial Long-term Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (The DEPICT-2 Study): 52-week Results From a Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Apr 20. doi: 10.1111/dom.14060. Online ahead of print. Long-term Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (The DEPICT-2 Study): 52-week Results From a Randomized Controlled Trial

2020 EvidenceUpdates

9. Effects of an Electronic Software Prompt With Health Care Professional Training on Cardiovascular and Renal Complications in a Multiethnic Population With Type 2 Diabetes and Microalbuminuria (the GP-Prompt Study): Results of a Pragmatic Cluster-Randomize

Software "Prompt" With Health Care Professional Training on Cardiovascular and Renal Complications in a Multiethnic Population With Type 2 Diabetes and Microalbuminuria (The GP-Prompt Study): Results of a Pragmatic Cluster-Randomized Trial , , , , , , , Affiliations Expand Affiliations 1 Diabetes Research Centre, University of Leicester, Leicester, U.K. 2 National Institute for Health Research Applied Research Collaboration (ARC) East Midlands, Leicester, U.K. 3 George Eliot Hospital National Health (...) Effects of an Electronic Software Prompt With Health Care Professional Training on Cardiovascular and Renal Complications in a Multiethnic Population With Type 2 Diabetes and Microalbuminuria (the GP-Prompt Study): Results of a Pragmatic Cluster-Randomize Effects of an Electronic Software "Prompt" With Health Care Professional Training on Cardiovascular and Renal Complications in a Multiethnic Population With Type 2 Diabetes and Microalbuminuria (The GP-Prompt Study): Results of a Pragmatic

2020 EvidenceUpdates

10. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial Full Text available with Trip Pro

Cite Abstract Background: Given the unique phenotype of type 2 diabetes in Japanese patients, novel therapies such as oral semaglutide require evaluation in this population. PIONEER 9 aimed to assess the dose-response of oral semaglutide and to compare the efficacy and safety of oral semaglutide with placebo and a subcutaneous GLP-1 receptor agonist in a Japanese population. Methods: PIONEER 9 was a 52-week, phase 2/3a, randomised, controlled trial done at 16 sites (clinics and university hospitals (...) ) in Japan. Japanese patients aged 20 years or older with uncontrolled type 2 diabetes managed by diet or exercise or with oral glucose-lowering drug monotherapy (washed out) were randomly assigned (1:1:1:1:1) to receive double-blind once-daily oral semaglutide (3 mg, 7 mg, or 14 mg) or placebo, or open-label subcutaneous once-daily liraglutide 0·9 mg. The primary endpoint was change in HbA 1c from baseline to week 26 with the trial product (primary) estimand (which assumes all patients remained on trial

2020 EvidenceUpdates

11. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

the safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes. Methods: PIONEER 10 was an open-label, randomised, active-controlled, phase 3a trial done at 36 sites (clinics and university hospitals) in Japan. Patients aged 20 years and older with uncontrolled type 2 diabetes were randomly assigned (2:2:2:1) to receive once-daily oral semaglutide 3 mg, 7 mg, or 14 mg, or once-weekly subcutaneous dulaglutide 0·75 mg for 52 weeks, as an add-on to their background (...) ) with dulaglutide (estimated treatment difference -2·6 kg [95% CI -3·5 to -1·6] for oral semaglutide 14 mg vs dulaglutide; p<0·0001). Interpretation: Oral semaglutide was well tolerated in Japanese patients with type 2 diabetes. Once-daily oral semaglutide significantly reduced HbA 1c (14 mg dose) and bodyweight (7 mg and 14 mg doses) versus weekly subcutaneous dulaglutide 0·75 mg by week 52. Funding: Novo Nordisk. Copyright © 2020 Elsevier Ltd. All rights reserved. Similar articles Mosenzon O, Blicher TM

2020 EvidenceUpdates

12. Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study

Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health (...) Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Jul;43(7):1553-1556. doi: 10.2337/dc19-1944. Epub 2020 Apr 28. Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Endocrinology, Department of Pediatrics, The Hospital

2020 EvidenceUpdates

13. Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study Full Text available with Trip Pro

Partners, Birmingham, U.K. 6 Midlands Health Data Research UK, Birmingham, U.K. PMID: 32345651 DOI: Item in Clipboard Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study Nicola J Adderley et al. Diabetes Care . 2020 . Show details Diabetes Care Actions . 2020 Apr 28;dc192116. doi: 10.2337/dc19-2116. Online ahead of print. Authors , , , , , , , , , , Affiliations 1 Institute of Applied Health (...) care database from 1 January 2005 to 17 January 2018. Participants aged ≥16 years with type 2 diabetes were included. Exposed participants were those who developed OSA after their diabetes diagnosis; unexposed participants were those without diagnosed OSA. Outcomes were composite CVD (ischemic heart disease [IHD], stroke/transient ischemic attack [TIA], heart failure [HF]), peripheral vascular disease (PVD), atrial fibrillation (AF), peripheral neuropathy (PN), diabetes-related foot disease (DFD

2020 EvidenceUpdates

14. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study

: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Apr 2. doi: 10.1111/dom.14041. Online ahead of print. Safety of Dapagliflozin in a Broad Population of Patients With Type 2 Diabetes: Analyses From the DECLARE-TIMI 58 Study , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Diabetes Unit, Department of Endocinology and Metabolism, Hadassah Medical Center, Hebrew University of Jerusalem (...) Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study Safety of Dapagliflozin in a Broad Population of Patients With Type 2 Diabetes: Analyses From the DECLARE-TIMI 58 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National

2020 EvidenceUpdates

15. ABCD position statement on standards of care for management of adults with type 1 diabetes

ABCD position statement on standards of care for management of adults with type 1 diabetes Standards of Care for Management of Adults with Type 1 Diabetes | ABCD (Diabetes Care) Ltd You are here: Standards of Care for Management of Adults with Type 1 Diabetes 2020 ABCD Standards of care for the management of adults with type 1 diabetes provides comprehensive standards for units providing care to people with type 1 diabetes and is intended as a resource for specialist teams. A summary document (...) is also available which includes a short summary of the recommendations from each section. The sections on inpatient care and management of diabetic emergencies are particularly relevant today. We are grateful to all the contributors. Discipline: Diabetes Clinical taxonomy: Type 1 diabetes mellitus Resource taxonomy: Guidelines Position Paper Information for HCPs Follow Us Address for correspondence: ABCD (Diabetes Care) Ltd, Miria House, 1683b High Street, Knowle, Solihull, West Midlands, B93 0LL

2020 Association of British Clinical Diabetologists

16. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. Full Text available with Trip Pro

Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. To estimate and compare progression rates to type 2 diabetes mellitus (T2DM) in women with gestational diabetes mellitus (GDM) and healthy controls.Systematic review and meta-analysis.Medline and Embase between January 2000 and December 2019, studies published in English and conducted on humans.Observational studies investigating progression to T2DM. Inclusion criteria were (...) postpartum follow-up for at least 12 months, incident physician based diagnosis of diabetes, T2DM reported as a separate outcome rather than combined with impaired fasting glucose or impaired glucose tolerance, and studies with both a group of patients with GDM and a control group.This meta-analysis of 20 studies assessed a total of 1 332 373 individuals (67 956 women with GDM and 1 264 417 controls). Data were pooled by random effects meta-analysis models, and heterogeneity was assessed by use of the I2

2020 BMJ

17. Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality

Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality Prescrire IN ENGLISH - Spotlight '' Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality'', 1 May 2020 {1} {1} {1} | | > > > Dulaglutide (Trulicity) and type 2 diabetes. No reduction in all-cause mortality or cardiovascular mortality Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |    (...) or cardiovascular mortality. Full text available for free download. Summary In a randomised, placebo-controlled trial i ncluding about 10 000 patients with type 2 diabetes and a mean HbA1c of 7.3% at enrolment, addition of dulaglutide to their usual hypoglycaemic therapy did not reduce all-cause or cardiovascular mortality after a follow-up of about 5 years. The increased risk of acute pancreatitis and pancreatic or thyroid cancer must be taken into account, as with any GLP-1 receptor agonist. Full text

2020 Prescrire

18. Management of Hypoglycaemia in Children and Young People with Type 1 Diabetes

Management of Hypoglycaemia in Children and Young People with Type 1 Diabetes ssociation of Children’s Diabetes Clinicians Clinicians Version 4, May 2018 Review 2021 Authors: SM Ng, E Williams, F Ackland, C Burren, J Edge, E Hind, A McAulay, Bill Lamb 1 SETTING Children and young people with diabetes mellitus PATIENTS Children and young people with diabetes mellitus Guidance • Definition of hypoglycaemia in children with diabetes is a blood glucose 4.0mmol/L, Retest 20-30 minutes later (...) and caregivers, especially when there is a high risk of severe hypoglycaemia. Education on administration of glucagon is essential Blood glucose monitoring should be performed prior to exercise, and extra carbohydrates should be consumed based on the blood glucose level and the expected intensity and duration of the exercise REFERENCE 1. NICE (2015) Diabetes (type 1 and type 2) in children and young people. NICE guideline NG18 www.nice.org.uk/guidance/ng18 2. ISPAD Clinical Practice Consensus Guidelines 2014

2020 British Society for Paediatric Endocrinology and Diabetes

19. Care of the Well Child-Newly Diagnosed with Type 1 Diabetes

Care of the Well Child-Newly Diagnosed with Type 1 Diabetes Version 4, Dec 2019 Review 2022 Authors: J Chizo Agwu, SM Ng, A Timmis, C Moudiotis, K. Matyka,, N.P.Wright, M. Kershaw S.Bahl, A. Alston . N Trevelyan Page of 7 1 ssociation of Children’s Diabetes Clinicians Clinical Guideline Care of the well child, newly diagnosed with Type 1 Diabetes Mellitus SETTING Insert hospital name FOR STAFF Medical and nursing staff PATIENTS Children with diabetes and their families (...) to metabolic disturbance 12 . ? Antibody markers predicting type 1 diabetes: NICE advises against using Islet Cell Antibodies (ICA)and Glutamic Acid Decarboxylase Autoantibodies (GAD antibodies) to distinguish between Type 1 and other forms of diabetes, but they may be helpful as part of an overall clinical picture. o Antibody negative diabetes is not unusual. Reports suggest somewhere between 20 to 30% of children may be antibody negative at diagnosis 3,4 . Islet cell antibodies are more likely

2020 British Society for Paediatric Endocrinology and Diabetes

20. Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial

With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial Ambarish Pandey et al. Circulation . 2020 . Show details Circulation Actions . 2020 Apr 21;141(16):1295-1306. doi: 10.1161/CIRCULATIONAHA.119.044865. Epub 2020 Mar 5. Authors # , # , , , , , , , , , , Affiliations 1 Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas (A.P., K.V.P., D.K.M., J.D.B.). 2 Department of Biostatistics and Data Science (J.L.B., S.A.G.), Wake Forest (...) Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage

2020 EvidenceUpdates